SGO Meeting Highlights via Twitter ~ Day Three, March 14, 2017

I am at home watching the snow fall and following Tweets from The Society of Gynecologic Oncology (@SGO_org) Annual Meeting using the hashtag #SGOmtg.

Here are some tweets fromTuesday, March 14,2017 ( Pi day!)

Other sources of Meeting coverage:

Stay up to date on the #SGOMtg with our conference coverage! https://t.co/dzpWAtqAlW

— CURE Magazine (@cure_magazine) March 14, 2017

Endometrial Cancer

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer https://t.co/E0LI2OzxDO #SGOmtg

— OncLive.com (@OncLive) March 14, 2017

Sentinel lymph mode mapping is #costeffective for the treatment of #endometrial cancer! #SGOMtg #gyncsm #endcancer great job @SuidanRudy https://t.co/uZxo7RB7NV

— Shannon Westin (@ShannonWestin) March 14, 2017

Ovarian cancer
GOG-3003 Compares pegylated liposomal doxorubicin (PLD) to PLD in combination with motolimod (a new type of investigational drug that stimulates the immune system)

Motolimod is an agonist for TLR8 in GOG-3003. Combo with PLD in #ovariancancer had no improvement in OS or PFS. #SGOMtg

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

     SOLO2 Trial studied LYNPARZA as maintenance treatment for women with BRCA-mutated metastatic ovarian cancer

SOLO2 primary endpoint was PFS, not OS (key secondary endpt) #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

SOLO2 data presented at #SGOMtg: PFS advantage in olaparib maintenance arm for BRCAmut recurrent ovary cancer. Compelling. #parpi

— Jenny Mueller MD (@JennyMueller_) March 14, 2017

SOLO2:  Time to First Secondary Treatment- 27.9 months vs 7.1 (HR 0.28; p <0.0001) in favor of olaparib -  WOW!!!! #SGOMtg

— Tabari (@Tabari_B) March 14, 2017

37% using olaparib had a grade 3 or higher adverse event (vs 18% with placebo) #SOLO2 #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

GOG-212

Late breaking abstract time. First up GOG212. #SGOmtg pic.twitter.com/qcprT7KBBp

— Annie Ellis (@Stigetta) March 14, 2017

#SGOMtg #GOG212: example that more treatment is not always better.No improvement in OS despite slight PFS improvement.

— Deanna Teoh, M.D. (@DeannaTeoh) March 14, 2017

GOG212: Surveillance v Taxol x12 vs CT2103 x12. Primary endpoint OS. #SGOMtg Activated 12 years ago!

— Don S Dizon (@drdonsdizon) March 14, 2017

Both Taxol and CT-2103 showed clinically meaningful and worse neurotoxicity vs surveillance in GOG212 @copebuckeye #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

Stress

Fascinating research approach integrating basic science and big database looking at drug combo and stress in ov ca from @DrRobDood #SGOMtg pic.twitter.com/fsn0nB0ptE

— Katie Kurnit (@katiekurnit) March 14, 2017

Uterine Carcinosarcoma

TP53 mutations are most common in our study of carcinosarcoma #uterinecancer @nicoleflemingmd #endcancer #SGOMtg pic.twitter.com/maPL5RROhA

— Rebecca Previs (@BeccaPrevisMD) March 14, 2017

Cervical Cancer
AXAL :Phase 2 study axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix 

Improved OS over historical controls with AXAL in recurrent #cervical cancer! Big news.  #SGOMtg #gyncsm https://t.co/whlS6QOBBi

— Shannon Westin (@ShannonWestin) March 14, 2017

AXAL: live attenuated listeria based immnotherapy that secretes HPV-16 E7 protein fused with a truncated fragment of listeriolysin O #SGOMtg

— Don S Dizon (@drdonsdizon) March 14, 2017

General

#quality research improves outcomes!  Reduced blood transfusions = less cost and better outcomes. Great job @LPrescottMD #SGOMtg #gyncsm https://t.co/FJpqGHRDXe

— Shannon Westin (@ShannonWestin) March 14, 2017

Sunrise Session. Dr. Annunziata says Phase 2/3 trials and inclusion of biomarker targeting/analysis are the future #SGOMtg

— A.C. Evans, MD, PhD (@gynoncdoc) March 14, 2017

So thankful for a glimpse via tweets of research that can change the future of women with gynecologic cancers.

Dee
Every Day is a Blessing!